Quick-Med Technologies, Inc. and the University of Michigan Sign Patent Licensing Agreement

Gainesville, Florida - June 19, 2007 - Quick-Med Technologies, Inc. (OTC Bulletin Board: QMDT) ("QMT" or the "Company") is pleased to announce that it has signed a patent license agreement with the University of Michigan ("U-M") that significantly expands the Company's MultiStatT technology - its patented family of compounds for the cosmetic treatment of skin conditions, including chronological aging and photo-aging. The license grants QMT the exclusive right to commercialize important U-M patents in the field of cosmetic products.

The Company has been commercializing its MultiStat technology through an exclusive distribution agreement with BASF Corporation. Under the agreement, performance ingredients based on the Company's patented compounds are formulated and sold to the cosmetics industry.

"These patents significantly extend our patent estate in the cosmetics arena" stated Michael R. Granito, Chairman of Quick-Med Technologies, Inc. "Exclusive rights should give us the ability to strengthen our position in the market" Mr. Granito added.

The Company owns exclusive rights for topical use of the MultiStat compounds for cosmetic and military applications, but previously had non-exclusive patent rights for use of U-M patents in the anti-aging cosmetic arena. The agreement covers the exclusive rights to seven (7) U.S. and numerous foreign patents in cosmetics applications.

About MultiStat™

MultiStat is a family of advanced, patented compounds and methods that have shown in numerous academic studies significant benefit in promoting the appearance and maintenance of skin.

About Quick-Med Technologies, Inc.
Quick-Med Technologies is a life sciences company focused in developing proprietary, broad-based technologies for consumer, industrial, and healthcare use, as well as for advanced military and civilian medical applications. The Company¹s two core products under development are (1) MultiStat™, a family of advanced compounds shown to be effective in broad-based skin therapy applications, and (2) NIMBUS™, a family of advanced polymers that can be used in a wide range of applications from advanced wound care to wood preservatives. Quick-Med Technologies is listed under the symbol "QMDT" on the OTC Bulletin Board. For additional information, visit Quick-Med Technologies¹ website: www.quickmedtech.com or email: info@quickmed-technologies.com

For additional further information, please contact QMT:

David S. Lerner -- President
Phone : (561) 750-4202
Email: dlerner@quickmed-technologies.com

Natasha A. Sorobey -- Corporate & Investor Relations (Canada)
Phone: (403) 203-4748
Email: nsorobey@quickmed-technologies.com

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology is intended to identify forward-looking statements involve risks and uncertainties, including launch and approval of the potential products described herein and the Company¹s results of operations. The Company is also subject to other risks as detailed from time-to-time in the Company¹s SEC filings.